D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Microbiology D-index 57 Citations 14,572 201 World Ranking 1391 National Ranking 588

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Virus
  • Cancer

Douglas T. Dieterich mainly focuses on Internal medicine, Immunology, Hepatitis C virus, Ribavirin and Hepatitis C. As part of the same scientific family, Douglas T. Dieterich usually focuses on Internal medicine, concentrating on Gastroenterology and intersecting with Liver biopsy. His Immunology research includes elements of Clinical trial and Risk factor.

Douglas T. Dieterich studies Hepatitis C virus, namely Sofosbuvir. Ribavirin is a subfield of Virology that Douglas T. Dieterich investigates. His Hepatitis C study combines topics from a wide range of disciplines, such as Pharmacotherapy, Adverse effect, Acquired immunodeficiency syndrome and Viral load.

His most cited work include:

  • Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. (1123 citations)
  • Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. (400 citations)
  • Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study (367 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Internal medicine, Hepatitis C virus, Virology, Ribavirin and Hepatitis C. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Viral load, Immunology and Sofosbuvir. As part of one scientific family, Douglas T. Dieterich deals mainly with the area of Hepatitis C virus, narrowing it down to issues related to the Cirrhosis, and often Fibrosis.

His work in the fields of Virology, such as Virus, Faldaprevir, Hepatitis B virus and Interferon, intersects with other areas such as In patient. His Ribavirin research incorporates themes from Regimen, Adverse effect and Alpha interferon. His Hepatitis C research is multidisciplinary, incorporating elements of Direct acting, Surgery, Pharmacology and Hepatitis.

He most often published in these fields:

  • Internal medicine (47.37%)
  • Hepatitis C virus (32.63%)
  • Virology (30.53%)

What were the highlights of his more recent work (between 2015-2021)?

  • Internal medicine (47.37%)
  • Hepatitis C (29.47%)
  • Hepatitis C virus (32.63%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Internal medicine, Hepatitis C, Hepatitis C virus, Virology and Gastroenterology. His Internal medicine study incorporates themes from Surgery, Oncology and Ribavirin, Genotype, Sofosbuvir. His research on Hepatitis C also deals with topics like

  • Liver disease that connect with fields like Immunology,
  • Direct acting, which have a strong connection to Antiviral treatment.

His studies in Hepatitis C virus integrate themes in fields like Interquartile range, Viral load, Hepatocellular carcinoma, Prospective cohort study and Drug. In general Virology study, his work on Telaprevir and Virus often relates to the realm of In patient, thereby connecting several areas of interest. Douglas T. Dieterich has researched Gastroenterology in several fields, including Nonalcoholic fatty liver disease and Liver transplantation.

Between 2015 and 2021, his most popular works were:

  • American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. (128 citations)
  • Real-world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the Trio Health study (55 citations)
  • Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. (47 citations)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Francesca J. Torriani;Maribel Rodriguez-Torres;Jürgen K. Rockstroh;Eduardo Lissen.
The New England Journal of Medicine (2004)

1682 Citations

Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study

Naga Chalasani;Herbert L. Bonkovsky;Robert Fontana;William M Lee.
Gastroenterology (2015)

493 Citations

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

Susanna Naggie;Curtis Cooper;Michael Saag;Kimberly Workowski.
The New England Journal of Medicine (2015)

492 Citations

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

Emmet B. Keeffe;Stefan Zeuzem;Raymond S. Koff;Douglas T. Dieterich.
Clinical Gastroenterology and Hepatology (2007)

469 Citations

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

David L. Wyles;Peter J. Ruane;Mark S. Sulkowski;Douglas Dieterich.
The New England Journal of Medicine (2015)

463 Citations

A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin

Mark G. Swain;Ming–Yang Lai;Mitchell L. Shiffman;W. Graham E. Cooksley.
Gastroenterology (2010)

460 Citations

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.

Nezam H. Afdhal;Douglas T. Dieterich;Paul J. Pockros;Eugene R. Schiff.
Gastroenterology (2004)

446 Citations

Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.

Vincent Soriano;Mark Sulkowski;Colm Bergin;Angelos Hatzakis.
AIDS (2002)

400 Citations

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

Mark S. Sulkowski;Susanna Naggie;Jacob Lalezari;Walford Jeffrey Fessel.
JAMA (2014)

339 Citations

Anemia in HIV Infection: Clinical Impact and Evidence-Based Management Strategies

Paul A. Volberding;Alexandra M. Levine;Douglas Dieterich;Donna Mildvan.
Clinical Infectious Diseases (2004)

303 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Douglas T. Dieterich

Vincent Soriano

Vincent Soriano

Hospital Universitario La Paz

Publications: 101

Mark S. Sulkowski

Mark S. Sulkowski

Johns Hopkins University School of Medicine

Publications: 86

Pablo Barreiro

Pablo Barreiro

Hospital Universitario La Paz

Publications: 62

Juan A. Pineda

Juan A. Pineda

Spanish National Research Council

Publications: 60

Raymond T. Chung

Raymond T. Chung

Harvard University

Publications: 58

Jürgen K. Rockstroh

Jürgen K. Rockstroh

University Hospital Bonn

Publications: 55

Gregory J. Dore

Gregory J. Dore

UNSW Sydney

Publications: 53

Antonio Rivero

Antonio Rivero

Instituto Maimónides de Investigación Biomédica de Córdoba

Publications: 50

Stanislas Pol

Stanislas Pol

Université Paris Cité

Publications: 50

Kenneth E. Sherman

Kenneth E. Sherman

University of Cincinnati Medical Center

Publications: 49

Marina Núñez

Marina Núñez

Wake Forest University

Publications: 48

Jean-Michel Pawlotsky

Jean-Michel Pawlotsky

Université Paris Cité

Publications: 46

Gail V. Matthews

Gail V. Matthews

UNSW Sydney

Publications: 44

Luz Martín-Carbonero

Luz Martín-Carbonero

Hospital Universitario La Paz

Publications: 43

David L. Thomas

David L. Thomas

University College London

Publications: 43

Massimo Puoti

Massimo Puoti

University of Brescia

Publications: 42

Trending Scientists

Ulf Olofsson

Ulf Olofsson

Royal Institute of Technology

Jackie Y. Ying

Jackie Y. Ying

Agency for Science, Technology and Research

Abdelhamid Sayari

Abdelhamid Sayari

University of Ottawa

Roberto Dovesi

Roberto Dovesi

University of Turin

Kyo Han Ahn

Kyo Han Ahn

Pohang University of Science and Technology

Marius Grundmann

Marius Grundmann

Leipzig University

Neil R. Hackett

Neil R. Hackett

Cornell University

Göran I. Ågren

Göran I. Ågren

Swedish University of Agricultural Sciences

Ewa Sikora

Ewa Sikora

Polish Academy of Sciences

Andrew E. Aplin

Andrew E. Aplin

Thomas Jefferson University

T. S. Keshava Prasad

T. S. Keshava Prasad

Yenepoya University

Bernard Thienpont

Bernard Thienpont

KU Leuven

Pier Francesco Ferrari

Pier Francesco Ferrari

Centre national de la recherche scientifique, CNRS

Marcus Lira Brandão

Marcus Lira Brandão

Universidade de São Paulo

Virginia W. Berninger

Virginia W. Berninger

University of Washington

Douglas A. Wolf

Douglas A. Wolf

Syracuse University

Something went wrong. Please try again later.